Chief Executive: Pharma CEOs Grapple With Huge R&D Costs

Chief Executive: Pharma CEOs Grapple With Huge R&D Costs

The topic busted out in the open when Turing Pharmaceuticals CEO Martin Shkreli last month hiked the price of 62-year-old Daraprim—a drug commonly used to treat patients with AIDS, cancer, and malaria—by about 5,445%.

In the face of mounting criticism, including from presidential candidates on both sides of the aisle, Turing eventually pushed the price down from $750 per pill to an undisclosed amount. (Business Insider)

Read more

Topics: News

Posted by

Truveris Team